A Phase 1b Study of Elranatamab Plus Carfilzomib and Dexamethasone or Elranatamab Plus PF-07901801 in People With Multiple Myeloma

Full Title

A Phase 1b, Open-Label Study of Elranatamab in Combination with Carfilzomib Plus Dexamethasone and Elranatamab in Combination with PF-07901801 in Participants with Relapsed Refractory Multiple Myeloma

Purpose

Researchers want to find the best dose of elranatamab when given with carfilzomib and dexamethasone or PF-07901801 in people with multiple myeloma. The people in this study have multiple myeloma that keeps growing or came back after treatment.

Elranatamab is already used alone in people with multiple myeloma. Its use in combination with other drugs is considered investigational. Elranatamab is a type of drug called a bispecific antibody. The antibodies in elranatamab bind to myeloma cells and immune system cells called T cells. Researchers think that giving elranatamab with carfilzomib and dexamethasone or with PF-07901801 may be better than giving it alone.

If you join this study, you will get one of these treatments:

• Elranatamab with carfilzomib and dexamethasone
• Elranatamab with PF-07901801

Who Can Join

To join this study, there are a few conditions. You must:

• Have multiple myeloma that keeps growing or came back after treatment.
• Have recovered from the serious side effects of prior therapies.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please call Dr. Alexander Lesokhin’s office at 646-608-2091.